Viyash Scientific

Viyash Scientific EBITDA per Employee

The EBITDA per Employee of Viyash Scientific (VIYASH.NS) as of Nov 4, 2026 is 3.50 M INR. In the previous year, EBITDA per Employee was 1.77 M INR — a change of 97.13% (higher).

EBITDA per Employee

3.50 MINR

YoY

97.13%

Last updated:

EBITDA per Employee of Viyash Scientific is 2025 3.50 M INR. EBITDA per Employee of Viyash Scientific was 2024 1.77 M INR. It decreases by 97.13% higher compared to the previous year.

The Viyash Scientific EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
1.83 M INR
Jan 1, 2019
2.78 M INR
Jan 1, 2020
3.68 M INR
Jan 1, 2021
4.53 M INR
Jan 1, 2022
2.29 M INR
Jan 1, 2023
844,079.50 INR
Jan 1, 2024
1.77 M INR
Jan 1, 2025
3.50 M INR
The Viyash Scientific EBITDA per Employee history
YEAREBITDA per EmployeeYoY
3.50 MINR+97.13%
1.77 MINR+110.21%
844,079.50INR-63.12%
2.29 MINR-49.42%
4.53 MINR+23.04%
3.68 MINR+32.48%
2.78 MINR+51.48%
1.83 MINR+46.49%
1.25 MINR-12.45%
1.43 MINR+223.70%
441,422.59INR+15.30%
382,845.19INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Viyash Scientific Stock analysis

What does Viyash Scientific do? Viyash Scientific Ltd generates revenue through the manufacturing and sale of veterinary pharmaceuticals and specialty chemicals. The company offers finished dose formulations, active pharmaceutical ingredients (APIs), and analytical services to clients in the pharmaceutical, personal care, and nutraceutical industries. Its products target therapies such as anthelmintics, anti-protozoals, nutraceuticals, NSAIDs, anti-infectives, and dermatology solutions. The firm operates primarily through its pharmaceuticals segment, with subsidiaries Alivira Animal Health Limited and SeQuent Research Limited supporting its analytical and bioanalytical service offerings. The company's analytical services include method validation, stability testing, microbiology, and in-house method development, adhering to pharmacopoeia monographs and customer-specific requirements. These services are provided to API, pharmaceutical, personal care, and nutraceutical companies seeking regulatory compliance and quality assurance. The firm's focus on targeted therapies and specialized services positions it to serve a niche market within the animal health sector. Viyash Scientific Ltd's revenue streams are derived from both product sales and service contracts. The pharmaceuticals segment, which includes APIs and finished formulations, represents a core business area, while analytical services form a complementary revenue source. The company leverages its subsidiaries to enhance its service capabilities, particularly in analytical and bioanalytical support for clients across multiple industries. Viyash Scientific is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Viyash Scientific stock

EBITDA per Employee of Viyash Scientific is 3.50 M INR in 2025.

EBITDA per Employee of Viyash Scientific changed from 1.77 M INR to 3.50 M INR, representing a 97.13% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Viyash Scientific since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Viyash Scientific historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Viyash Scientific

All Key Metrics — Viyash Scientific